%A Li Xueqin, Chen Xi, Gong Quan, Shi Wei, Zhang Lijuan, Dong Hui, Wang Cunde %T Clinical analysis of morphine hydrochloride sustainedrelease tablets combined with celecoxib in the treatment of advanced lung cancer with moderate to severe cancerinduced pain %0 Journal Article %D 2017 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673422X.2017.03.002 %P 165-168 %V 44 %N 3 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10166.shtml} %8 2017-03-08 %X ObjectiveTo explore the efficacy, safety and life quality of patients of morphine hydrochloride sustainedrelease tablets combined with celecoxib in the treatment of advanced lung cancer with moderate to severe cancerinduced pain. MethodsA total of 247 patients of advanced lung cancer with moderate to severe cancerinduced pain were randomly divided into combination therapy group (n=127) and morphine monotherapy group (n=120) using simple random sampling digital table method. The differences of dose, efficacy, adverse drug reactions and life quality between the two groups were analyzed. ResultsIn achieving similar analgesic effect, the average maintenance dose of morphine in combination therapy group was (52.51±19.92)mg/d, lower than that in monotherapy group ［(58.75±20.64)mg/d, t=-2.414, P=0.017］. The incidence of constipation in combination therapy group was 34.6%, lower than that in monotherapy treatment group (47.5%, χ2=4.218, P=0.040). The life quality of the two groups were improved, and the life quality improvement rate in combination therapy group was 59.8%, higher than that in monotherapy treatment group (43.3%, χ2=6.736, P=0.009). ConclusionMorphine hydrochloride sustainedrelease tablets combined with celecoxib is effective in the treatment of moderate to severe cancer pain, which can reduce the dosage of morphine and reduce adverse reaction, so as to improve the life quality of the patients with advanced lung cancer.